All In Biotech

Drug Trial Radar · NCT07396441

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye

Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

May 15, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Universiti Sains MalaysiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hospital Raja Perempuan Zainab II, Kota Bahru, Kelantan; Hospital Sultanah Nur Zahirah, Kuala Terengganu; Hospital Universiti Sains Malaysia
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.

Conditions

  • Juvenile Open Angle Glaucoma
  • Dry Eye Disease (DED)
  • Interleukin 6
  • Retinal Nerve Fiber Layer Thickness
  • HbA1c Level

Interventions

  • Stingless bee honey (Kelulut)Biological

    Kelulut is stingless bee honey, a natural biologic product produced by stinglee bee species.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the level of serum Interleukin-6 level before and after consumption of stingless bee honey for 3 months among patients with juvenile open angle glaucomaTime frame: from the enrolment to the end of study at 90 days
  2. serum Interleukin 6 levelTime frame: 90 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Raja Perempuan Zainab II

    Kota Bharu, Kelantan, Malaysia · Recruiting

  • Hospital Sultan Ismail Petra

    Kuala Krai, Kelantan, Malaysia · Recruiting

  • Hospital Universiti Sains Malaysia

    Kubang Kerian, Kelantan, Malaysia · Recruiting

  • Hospital Sultanah Nur Zahirah

    Kuala Terengganu, Terengganu, Malaysia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.